March 24, 2021
Taiho Pharmaceutical said on March 23 that it has submitted a new drug application in Japan for its NK 1 receptor antagonist antiemetic fosnetupitant for the treatment of gastrointestinal symptoms (nausea/vomiting) associated with cancer chemotherapy. Fosnetupitant, for which Taiho has...read more